Table I.

Clinicopathological significance of the KIF18A expression ratio in breast cancer.

	KIF18A expression ratio
	Low		High
Clinicopathological factor	n	%	n	%	P-value
Age, years (mean ± SD)	54.6±12.9		54.0±13.5		0.814
Menopause status					0.876
Pre	37	44.6	28	45.9
Post	46	55.4	33	54.1
Tumor stage					0.110
T1	34	40.9	33	54.1
T2-3	49	59.1	28	45.9
Lymph node metastasis					0.047a
Absent	62	74.7	36	59.1
Present	21	25.3	25	40.9
Lymphatic invasion					0.649
Absent	44	53.0	30	49.2
Present	39	47.0	31	50.8
Venous invasion					0.929
Absent	47	56.6	35	57.4
Present	36	43.4	26	42.6
Nuclear grade					0.185
Grade 1	47	56.6	40	65.6
Grade 2	15	18.1	13	21.3
Grade 3	21	25.3	8	13.1
Nuclear atypia					0.528
Score 1	5	6.0	6	9.8
Score 2	66	79.5	49	80.4
Score 3	12	14.5	6	9.8
Mitotic counts					0.256
Score 1	48	57.8	41	67.2
Score 2	17	20.5	13	21.3
Score 3	18	21.7	7	11.5
Estrogen receptor					0.961
Absent	12	14.5	9	14.8
Present	71	85.5	52	85.2
Progesterone receptor					0.629
Absent	22	26.5	14	22.9
Present	61	73.5	47	77.1
HER2 score					0.221
0–1	69	83.1	55	90.2
2–3	14	16.9	6	9.8
Recurrence					0.534
Absent	69	83.1	53	16.9
Present	14	86.9	8	13.1

^aP<0.05, statistical significance. KIF18a, kinesin family member 18A; SD, standard deviation; HER2, human epidermal growth factor receptor 2.